EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma

Akira Saito, Hiroki Ishihara, Hanae Kondo, Toshio Takagi iD, Yasunobu Hashimoto

IJU Case Reports · 2026-03 · 9 (2)

DOI: 10.1002/iju5.70148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 05.02.2026. Verfasst von Akira Saito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Saiseikai Kawaguchi General Hospital Saitama Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anti‐melanoma differentiation‐associated gene 5 antibody‐positive interstitial lung disease is a rare but fatal adverse event following immune checkpoint inhibitor treatment for cancers. However, such cases have not been previously reported in patients with urothelial carcinoma. Case Presentation A 79‐year‐old Japanese woman with advanced unresectable bladder cancer was treated with first‐line enfortumab vedotin plus pembrolizumab. During the second treatment cycle, interstitial lung disease developed, and the patient immediately received steroid pulse therapy. As interstitial lung disease rapidly progressed after the initiation of steroid pulse therapy, immunosuppressive treatment with cyclophosphamide and tacrolimus was added. However, interstitial lung disease did not improve, and the patient died on day 54 after initiating treatment. Detailed antibody examination revealed positive anti‐melanoma differentiation‐associated gene 5 antibodies.

Conclusion

We report the first case of anti‐melanoma differentiation‐associated gene 5 antibody‐positive interstitial lung disease induced by enfortumab vedotin plus pembrolizumab in a patient with advanced urothelial carcinoma.

Schlagwörter

Stichwörter der Autor:innen

anti‐melanoma differentiation‐associated gene 5 antibodiesbladder cancerdermatomyositisenfortumab vedotin plus pembrolizumabimmune‐related adverse events

Autor:innen und Institutionen

  • Department of Urology Saiseikai Kawaguchi General Hospital Saitama Japan.
  • Department of Urology Tokyo Women's Medical University Tokyo Japan.

ORCID-Profile: Toshio Takagi

Zitieren

APA

Saito, A., Ishihara, H., Kondo, H., Takagi, T., & Hashimoto, Y. (2026). Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma. IJU Case Reports, 9(2). https://doi.org/10.1002/iju5.70148

Vancouver

Saito A, Ishihara H, Kondo H, Takagi T, Hashimoto Y. Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma. IJU Case Reports. 2026;9(2). doi:10.1002/iju5.70148

BibTeX
@article{Saito2026,
  author = {Saito, Akira and Ishihara, Hiroki and Kondo, Hanae and Takagi, Toshio and Hashimoto, Yasunobu},
  title = {Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {2},
  doi = {10.1002/iju5.70148}
}
Kostenlos starten →